Content Area

DOSAGE AND ADMINISTRATION

Cialis > cialis tadalafil 10mg tablets


lopinavir will increase the cialis daily generic level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nelfinavirnelfinavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Storage Conditions Recommended Temperature Humidity Shelf Life Additional Notes
In a cool, dry place 20°C to 25°C <60% 2-3 years Keep out of direct sunlight
Away from moisture Controlled environment Store in original packaging
Keep out of reach of children Ambient conditions Ensure safety from accidental ingestion

nelfinavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nicardipinenicardipine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nicardipine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid coadministration if tadalafil used for pulmonary arterial hpertension. Reduce tadalafil dose if used for erectile dysfunction.

Medical uses

Avoid concurrent use of tadalafil for pulmonary HTN in patients taking strong CYP3A4 inhibitors. clarithromycin will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cobicistatcobicistat will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust tadalafil dose for PAH; if on cobicistat, start tadalafil 20 mg/day and may increase up to 40 mg/day; avoid tadalafil when starting cobicistat; for ED, may take a single dose of tadalafil not exceeding 10 mg in 72 hr. cobicistat will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Canadian Brand Name

darunavirdarunavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. darunavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. enzalutamideenzalutamide will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. enzalutamide will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. erythromycin baseerythromycin base will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Tadalafil dosage guide: key rules

erythromycin base will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. erythromycin ethylsuccinate will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. erythromycin lactobionate will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. erythromycin stearateerythromycin stearate cialis 5 miligramos will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. erythromycin stearate will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nirmatrelvir/ritonavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ritonavirritonavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Product Dosage Quantity + Bonus Price
Cialis Black80mg30 + 2 Pills89.11€ 84.87€
Cialis Generic40mg270 + 10 Pills382.19€ 363.99€
Cialis Professional20mg120 + 4 Pills291.68€ 277.79€
Cialis Original20mg8 Pills61.70€ 58.76€
Cialis Black80mg90 + 6 Pills207.88€ 197.98€
Cialis Generic2.5mg120 + 6 Pills128.93€ 122.79€
Cialis Generic2.5mg30 + 4 Pills51.95€ 49.48€
Cialis Professional40mg120 + 4 Pills436.68€ 415.89€
Cialis Generic40mg180 + 10 Pills277.29€ 264.09€
Cialis Generic60mg180 + 10 Pills313.11€ 298.20€
Cialis Super Active20mg270 + 30 Pills661.49€ 629.99€

ritonavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tovorafenibtovorafenib will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid coadministration of tovorafenib (a weak CYP3A4 inducer) with CYP3A substrates where minimal concentration changes may lead to serious therapeutic failures. If unavoidable, monitor patients for loss of efficacy unless otherwise recommended in the CYP3A4 substrate prescribing information.

Parameter Value Description Note
Absorption time 30-60 minutes Time to reach peak plasma levels Takes about 1 hour for maximum effect
Half-life 17.5 hours Duration of active drug in body Allows for once-daily dosing
Bioavailability 80% Percentage absorbed into circulation High absorption efficiency
Metabolism Liver (via CYP3A4 enzyme) Breakdown of drug Consider interactions with CYP3A4 inhibitors

tovorafenib will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tucatinibtucatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

8.1 Pregnancy

fexinidazolefexinidazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration may increase risk for adverse effects of CYP3A4 substrates. fexinidazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fosamprenavirfosamprenavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fosamprenavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Erectile Dysfunction

idelalisibidelalisib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates idelalisib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. itraconazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ketoconazoleketoconazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. CYP3A4 inhibitors may reduce tadalafil clearance increasing systemic exposure to tadalafil; significantly increased levels may result in significant adverse events including severe hypotension, syncope, visual changes, and priapism.

Dosage for BPH

ketoconazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lenacapavirlenacapavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Refer to the prescribing information of PDE5 inhibitors for dose recommendations. lenacapavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. levoketoconazolelevoketoconazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling. tucatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. acebutololtadalafil increases effects of acebutolol by pharmacodynamic synergism. tadalafil increases effects of acebutolol by pharmacodynamic synergism. acetazolamidetadalafil increases effects of acetazolamide by pharmacodynamic synergism. tadalafil increases effects of acetazolamide by pharmacodynamic synergism.

  • [Part of a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors.]
  • [Other PDE5 inhibitors include sildenafil (Viagra) and vardenafil (Levitra).]
  • [Tadalafil is distinguished by its significantly longer duration of action.]
  • [Choice of medication depends on individual response, side effects, and lifestyle.]
  • [Do not take tadalafil concurrently with other PDE5 inhibitors.]

alfuzosintadalafil increases effects of alfuzosin by pharmacodynamic synergism. tadalafil increases effects of alfuzosin by pharmacodynamic synergism.

5.4 Eye

Either increases effects of the other by pharmacodynamic synergism. Coadministration of vericiguat with PDE-5 inhibitors may result in additive hypotensive effects. apalutamideapalutamide will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible.

Dosing Modifications

Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed. apalutamide will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. atazanaviratazanavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Stop tadalafil >24 hours prior to protease inhibitor (PI) initiation, restart 7 days after PI initiation at 20 mg once daily, and increase to 40 mg once daily based on tolerability.

Oral Administration

atazanavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ceritinibceritinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ceritinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. clarithromycinclarithromycin will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. For ED limit tadalafil to max of 2.5 mg/day (for daily use) or 10 mg dose every 72 hr (for use as needed). aliskirentadalafil increases effects of aliskiren by pharmacodynamic synergism.

  • [Not approved for use in women or children.]
  • [Should not be used by men for whom sexual activity is inadvisable due to heart conditions.]
  • [Use with caution in patients with severe liver or kidney impairment; dose adjustment may be needed.]
  • [Can cause a temporary drop in blood pressure, leading to dizziness or fainting.]
  • [Patients with a history of stroke or heart attack should discuss risks thoroughly.]

tadalafil increases effects of aliskiren by pharmacodynamic synergism. Monitor blood pressure response to phosphodiesterase type 5 (PDE5) inhibitors in patients receiving concurrent blood pressure lowering therapy.

Special Cases

levoketoconazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lonafarniblonafarnib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling. lonafarnib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lopinavirlopinavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. amiloridetadalafil increases effects of amiloride by pharmacodynamic synergism.

Side Effect Frequency Severity Recommended Action
Headache Common Mild Usually temporary; OTC pain relief can help
Dyspepsia (Indigestion) Common Mild Dietary adjustments or antacids
Muscle Aches Less common Mild Rest or analgesics
Flushing Common Mild Cooling measures; usually transient
Vision Changes Rare Moderate Seek medical advice if sudden vision disturbance occurs

tadalafil increases effects of amiloride by pharmacodynamic synergism. amiodaroneamiodarone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. CYP3A4 inhibitors may reduce tadalafil clearance increasing systemic exposure to tadalafil; increased levels may result in increased associated adverse events. amiodarone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. amlodipinetadalafil increases effects of amlodipine by pharmacodynamic synergism. tadalafil increases effects of amlodipine by pharmacodynamic synergism. aprepitantaprepitant will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. aprepitant will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.